The data gathered by Wenjing et al. demonstrated that exendin-4, an incretin mimetic drug, inhibits growth and enhances apoptosis of ovarian cancer cells through inhibition of the PI3K/Akt pathway [26]. This evidence concerns the gene AKT1 and ovarian carcinoma.